
Atsena Therapeutics ATSENA THERAPEUTICS is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. We have two ongoing Phase I/II clinical trials evaluating potential therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Our lead program is evaluating ATSN-201 for XLRS, a genetic condition that is typically diagnosed in childhood and leads to blindness later in life. We are also developing ATSN-101, an investigational gene therapy for LCA1, in clinical trials in collaboration with Nippon Shinyaku Co., Ltd. Pivotal trials evaluating both ATSN-201 and ATSN-101 willare planned to begin in 2026. Our proprietary pipeline includes gene therapies in development for Usher Syndrome Type 1B and for Stargardt Disease. Therapeutic Developer

Atsena Therapeutics

ATSENA THERAPEUTICS is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. We have two ongoing Phase I/II clinical trials evaluating potential therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Our lead program is evaluating ATSN-201 for XLRS, a genetic condition that is typically diagnosed in childhood and leads to blindness later in life. We are also developing ATSN-101, an investigational gene therapy for LCA1, in clinical trials in collaboration with Nippon Shinyaku Co., Ltd. Pivotal trials evaluating both ATSN-201 and ATSN-101 willare planned to begin in 2026. Our proprietary pipeline includes gene therapies in development for Usher Syndrome Type 1B and for Stargardt Disease.

Therapeutic Developer